ONCOLYTICS BIOTECH INC.Warrant Indenture • May 31st, 2018 • Oncolytics Biotech Inc • Pharmaceutical preparations • Alberta
ONCOLYTICS BIOTECH INC., a corporation incorporated under the laws of the Province of Alberta having an office at 210, 1167 Kensington Crescent N.W., Calgary, Alberta
ONCOLYTICS BIOTECH INC. US$65,000,000 equity distribution AGREEMENTEquity Distribution Agreement • June 17th, 2022 • Oncolytics Biotech Inc • Pharmaceutical preparations • New York
Oncolytics Biotech Inc., a company incorporated under the Business Corporations Act (Alberta) (the “Company”), confirms its agreement (this “Agreement”) with Canaccord Genuity LLC (“Canaccord”), as follows:
UNDERWRITING AGREEMENT 4,619,773 Common Shares and 4,619,773 Warrants ONCOLYTICS BIOTECH Inc. (incorporated under the Business Corporations Act (Alberta))Underwriting Agreement • August 16th, 2019 • Oncolytics Biotech Inc • Pharmaceutical preparations • New York
Oncolytics Biotech Inc., a company incorporated under the Business Corporations Act (Alberta) (the "Company"), proposes to sell to the several underwriters named in Schedule I hereto (the "Underwriters") for whom Ladenburg Thalmann & Co. Inc. is acting as representative (the "Representative"), an aggregate of (i) 4,619,773 common shares (each, a "Firm Share"), no par value, of the Company (the "Common Shares"), and (ii) 4,619,773 Common Share purchase warrants (the “Firm Warrants”). The Company also proposes to grant to the Underwriters an option to purchase up to (i) 692,965 additional Common Shares (the "Option Shares" and, together with the Firm Shares, the "Shares"), and (ii) 692,965 additional warrants (the “Option Warrants” and together with the Firm Warrants, the “Warrants”). The common shares issuable upon exercise of the Firm Warrants and the Option Warrants are collectively referred to as the “Warrant Shares.” The Firm Shares, the Option Shares, the Firm Warrants, the Option
PURCHASE AGREEMENTPurchase Agreement • September 28th, 2018 • Oncolytics Biotech Inc • Pharmaceutical preparations • New York
THIS PURCHASE AGREEMENT (the “Agreement”), dated as of September 27, 2018 (the “Execution Date”), is entered into by and between ONCOLYTICS BIOTECH INC., a company incorporated under the Business Corporations Act (Alberta) (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 23rd, 2008 • Oncolytics Biotech Inc • Pharmaceutical preparations • Alberta
AND WHEREAS Oncolytics and the Employee wish to further amend and restate the terms of employment pursuant to this Agreement;
WARRANT INDENTURE Providing for the Issue of Warrants BETWEEN Oncolytics Biotech Inc. - and - Computershare Trust Company of Canada Dated as of February 12, 2007Warrant Indenture • February 15th, 2007 • Oncolytics Biotech Inc • Pharmaceutical preparations • Alberta
ONCOLYTICS BIOTECH INC. 4,250,000 Shares 1,700,000 Warrants UNDERWRITING AGREEMENTUnderwriting Agreement • November 18th, 2009 • Oncolytics Biotech Inc • Pharmaceutical preparations • New York
Oncolytics Biotech Inc., an Alberta corporation (the “Company”), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the “Underwriters”), for whom you are acting as Representative (the “Representative”), an aggregate of 4,250,000 units (the “Units”) of the Company (the “Underwritten Securities”), with each such Unit comprised of one of the Company’s common shares (the “Common Shares”), and 0.4 of one warrant to purchase Common Shares, with each whole warrant exercisable for one Common Share (each, a “Warrant” and collectively, the “Warrants”). The respective amounts of the Underwritten Securities to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. In addition, the Company proposes to grant to the Underwriters an option to purchase up to an additional 637,500 Common Shares (the “Option Shares”) and/or up to an additional 255,000 Warrants (
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 6th, 2020 • Oncolytics Biotech Inc • Pharmaceutical preparations • Alberta
AND WHEREAS Oncolytics and the Employee entered into an Executive Employment Agreement dated January 1, 2013, which has been amended;
AMENDING AGREEMENTExecutive Employment Agreement • March 19th, 2014 • Oncolytics Biotech Inc • Pharmaceutical preparations • Alberta
WHEREAS the Employee is an officer of Oncolytics whose terms of employment are set forth in the Executive Employment Agreement ("Employment Agreement") dated effective January 1, 2013;
EMPLOYMENT AGREEMENTEmployment Agreement • March 12th, 2024 • Oncolytics Biotech Inc • Pharmaceutical preparations • California
THIS EMPLOYMENT AGREEMENT (“Agreement”), effective September 1, 2020 (“Effective Date”), is made between Oncolytics Biotech (U.S.), Inc., (“Employer” or the “Company”), and Amy Goodowitz Levin (“Employee”). Employee and the Company are sometimes referred to herein as the “Parties.”
Oncolytics Biotech Inc. and American Stock Transfer & Trust Company, LLC, as Warrant Agent Warrant Agent Agreement Dated as of August 16, 2019 WARRANT AGENT AGREEMENTWarrant Agent Agreement • August 16th, 2019 • Oncolytics Biotech Inc • Pharmaceutical preparations • New York
WARRANT AGENT AGREEMENT, dated as of August 16, 2019 (“Agreement”), between Oncolytics Biotech Inc., a company incorporated under the Business Corporations Act (Alberta) (the “Company”), and American Stock Transfer & Trust Company, LLC a New York limited liability trust company (the “Warrant Agent”).
AMENDING AGREEMENT #1Executive Employment Agreement • March 6th, 2020 • Oncolytics Biotech Inc • Pharmaceutical preparations • Alberta
WHEREAS Oncolytics and the Employee entered into an Executive Employment Agreement dated January 1, 2019 (the “Employment Agreement”);
Oncolytics Biotech® Inc. and Adlai Nortye Enter into USD $86.6 Million Regional Licensing Agreement for REOLYSIN®Regional Licensing Agreement • November 17th, 2017 • Oncolytics Biotech Inc • Pharmaceutical preparations
· Oncolytics to receive upfront, licensing fee and milestone payments to support phase 3 registration study of USD $21.2 million, and eligible to receive up to an additional USD $65.4 million upon achievement of clinical, regulatory and commercialization milestones
AMENDING AGREEMENTExecutive Employment Agreement • March 24th, 2016 • Oncolytics Biotech Inc • Pharmaceutical preparations • Alberta
WHEREAS the Employee is an officer of Oncolytics whose terms of employment are set forth in the Executive Employment Agreement ("Employment Agreement") dated effective January 1, 2013;
AMENDMENT NO. 1 TO PURCHASE AGREEMENTPurchase Agreement • August 8th, 2014 • Oncolytics Biotech Inc • Pharmaceutical preparations • New York
This Amendment No. 1 (the “Amendment”) is entered into this 8th day of August 2014 (“Amendment Effective Date”), by and between ONCOLYTICS BIOTECH INC., a company incorporated under the Business Corporations Act (Alberta), (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”), and amends that certain Purchase Agreement, dated as of February 27, 2014, between the Investor and the Company (the “Agreement”). Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement.
AMENDING AGREEMENTEmployment Agreement • March 3rd, 2023 • Oncolytics Biotech Inc • Pharmaceutical preparations
This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument. In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.
ONCOLYTICS BIOTECH INC. Warrant Purchase AgreementWarrant Purchase Agreement • May 31st, 2018 • Oncolytics Biotech Inc • Pharmaceutical preparations • Hong Kong
Oncolytics Biotech Inc., a corporation organized under the laws of the Province of Alberta, Canada, (the “Company”), and ADLAI NORTYE BIOPHARMA CO., LTD., the registered holder hereof or its permitted assigns (the “Holder”), hereby agree that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Holder is entitled, subject to the terms and conditions set forth below in this Warrant Purchase Agreement (the “Warrant”) dated effective November 14, 2017 (the “Effective Date”), to purchase from the Company, at the Exercise Price (as defined below) then in effect, such number of fully paid and non-assessable Common Shares (as defined below) (the “Warrant Shares”), as calculated below. Except as otherwise defined herein, capitalized terms in this Warrant shall have the meanings set forth in Section 16. This Warrant is issued pursuant to Section 10.2 of that certain License, Development, Supply and Distribution Agreement, dated as of November 14, 2
AMENDING AGREEMENT #2Executive Employment Agreement • March 5th, 2021 • Oncolytics Biotech Inc • Pharmaceutical preparations • Alberta
WHEREAS Oncolytics and the Employee entered into an Executive Employment Agreement dated January 1, 2019 amended by Amending Agreement #1 dated January 1, 2020 (together the “Employment Agreement”);
SERVICES AGREEMENTServices Agreement • June 27th, 2003 • Oncolytics Biotech Inc • Pharmaceutical preparations • Alberta
ONCOLYTICS BIOTECH INC. equity distribution AGREEMENTEquity Distribution Agreement • March 12th, 2021 • Oncolytics Biotech Inc • Pharmaceutical preparations • New York
Oncolytics Biotech Inc., a company incorporated under the Business Corporations Act (Alberta) (the “Company”), confirms its agreement (this “Agreement”) with Canaccord Genuity LLC (“Canaccord”), as follows:
AMENDING AGREEMENT #1Employment Agreement • March 5th, 2021 • Oncolytics Biotech Inc • Pharmaceutical preparations • California
WHEREAS the Employee is an officer of OBUS whose terms of employment are set forth in the Employment Agreement dated effective August 3, 2020, (the “Employment Agreement”);
AMENDING AGREEMENT NO. 2 THIS AMENDING AGREEMENT made effective as of the 10th day of November, 2015. BETWEEN:Executive Employment Agreement • March 24th, 2016 • Oncolytics Biotech Inc • Pharmaceutical preparations
WHEREAS the Employee is an officer of OBUS whose terms of employment are set forth in the Executive Employment Agreement ("Employment Agreement") dated effective September 27, 2012;
AMENDING AGREEMENT #1Employment Agreement • March 19th, 2018 • Oncolytics Biotech Inc • Pharmaceutical preparations • California
WHEREAS the Employee is an officer of OBUS whose terms of employment are set forth in the Employment Agreement ("Employment Agreement") dated effective June 29, 2017;
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 6th, 2009 • Oncolytics Biotech Inc • Pharmaceutical preparations • California
AMENDING AGREEMENT # 3Employment Agreement • March 3rd, 2023 • Oncolytics Biotech Inc • Pharmaceutical preparations
This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument. In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.
AMENDMENT NO. 1Executive Employment Agreement • May 23rd, 2008 • Oncolytics Biotech Inc • Pharmaceutical preparations
WHEREAS Oncolytics and the Employee entered into an Executive Employment Agreement dated the 29th day of May, 2007 (the “Employment Agreement)”
AMENDING AGREEMENT NO. 2Executive Employment Agreement • March 20th, 2015 • Oncolytics Biotech Inc • Pharmaceutical preparations
WHEREAS the Employee is an officer of Oncolytics whose terms of employment are set forth in the Executive Employment Agreement ("Employment Agreement") dated effective January 1, 2013;
AMENDING AGREEMENT #2Executive Employment Agreement • March 5th, 2021 • Oncolytics Biotech Inc • Pharmaceutical preparations • Alberta
WHEREAS Oncolytics and the Employee entered into an Executive Employment Agreement dated January 1, 2019, amended by Amending Agreement #1 dated January 1, 2020 (together the “Employment Agreement”);
AMENDING AGREEMENT NO. 2Executive Employment Agreement • March 20th, 2015 • Oncolytics Biotech Inc • Pharmaceutical preparations
WHEREAS the Employee is an officer of Oncolytics whose terms of employment are set forth in the Executive Employment Agreement ("Employment Agreement") dated effective January 1, 2013;
Settlement AgreementSettlement Agreement • March 28th, 2017 • Oncolytics Biotech Inc • Pharmaceutical preparations • Alberta
AMENDING AGREEMENT #4Employment Agreement • March 5th, 2021 • Oncolytics Biotech Inc • Pharmaceutical preparations • California
WHEREAS the Employee is an officer of OBUS whose terms of employment are set forth in the Employment Agreement dated effective June 29, 2017, as amended by Amending Agreement #1, Amending Agreement #2 and Amending Agreement #3 (collectively the “Employment Agreement”);
AMENDMENT NO. 1Executive Employment Agreement • May 23rd, 2008 • Oncolytics Biotech Inc • Pharmaceutical preparations
WHEREAS Oncolytics and the Employee entered into an Executive Employment Agreement dated the 30th day of May, 2007 (the “Employment Agreement”);
AMENDING AGREEMENT NO. 4Employment Agreement • June 27th, 2003 • Oncolytics Biotech Inc • Pharmaceutical preparations
WHEREAS Oncolytics and Coffey entered into an Employment Agreement dated the 29th day of July, 1999 (the “Employment Agreement”) which has been amended by Amending Agreements dated September 24, 1999, January 1, 2001 and January 1, 2002;
AMENDING AGREEMENT # 4Executive Employment Agreement • March 3rd, 2023 • Oncolytics Biotech Inc • Pharmaceutical preparations
This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument. In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.
AMENDING AGREEMENT #1Employment Agreement • March 6th, 2020 • Oncolytics Biotech Inc • Pharmaceutical preparations • California
WHEREAS the Employee is an officer of OBUS whose terms of employment are set forth in the Employment Agreement dated effective November 1, 2018, (the “Employment Agreement”);
